Charlotte Robinson

DocwireNews

Although cyclophosphamide (CYC) is a cornerstone of induction therapy in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), the risk factors for relapse in patients undergoing CYC therapy are not well understood. Gianmarco Lugli and a team of researchers set out to develop a clinically useful tool to score robust predictors of relapse in these patients. Their results were presented at the 61st European Renal Association Congress.Study participants came from Ireland, Italy, and Spain; were aged &gt;18 years; had a diagnosis of granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or eosinophilic granulomatosis with polyangiitis (EGPA); underwent induction treatment with intravenous (IV) or oral CYC; and had at least 12 months of follow-up.The research team used a multivariate Cox analysis to develop the Relapse Evaluation and Cyclophosphamide Treatment (REACT) score, assigning each predictor a certain number of weighted points in proportion to its &beta; regression coefficient.The baseline assessment included clinical data, lab testing, and measurement of signs of GPA, MPA, and EGPA in each organ system. Relapse was defined as the presence of one or more new vasculitis manifestation after a remission of at least 3 months. Remission was defined as no disease activity regardless of glucocorticoid use. The Kaplan-Meier method was used to estimate time-to-remission and relapse-free survival probabilities.There were 505 patients in the cohort; 223 (44.2%) had MPA, 217 (43.0%) had GPA, and 65 (12.9%) had EGPA. Of the total cohort, 183 (36.2%) patients experienced an AAV relapse. Multivariate Cox analysis found that independent risk factors for relapse included proteinase 3-ANCA (hazard ratio [HR], 1.30; 95% CI, 1.01-1.87), IV CYC (HR, 1.78; 95% CI, 1.31-2.41), cardiovascular (CV) involvement (HR, 1.82; 95% CI, 1.01-3.25), arthralgias/arthritis (HR, 1.46; 95% CI, 1.08-1.98), and the absence of rapidly progressive glomerulonephritis (HR, 1.37; 95% CI, 1.02-1.85).For the creation of the REACT score, CV involvement and IV CYC each received two points, but otherwise each variable was assigned one point. Researchers identified three risk categories according to each patient&rsquo;s score: low risk of relapse (score zero or one), which comprised 138 (27%) patients; intermediate risk (score two or three), with 252 (49%) patients; and high risk (score four to seven), which included 115 (22%) patients. Kaplan-Meier analysis with paired comparisons between the risk groups found statistically significant differences in relapse probabilities among them.The study authors concluded, &ldquo;The REACT score can be employed at diagnosis to predict the risk of relapse in patients with AAV treated with [CYC] induction. Its value needs to be confirmed in external cohorts.&rdquo;Source: Lugli G, Buscemi P, Calatroni M, et al. <a href="https://doi.org/10.1093/ndt/gfae069.019" target="_blank" rel="noopener">Development of a relapse risk score in patients with ANCA-associated vasculitis treated with cyclophosphamide induction.</a> Abstract #1484. Presented at the 61st European Renal Association Congress; May 23-26, 2024; Stockholm, Sweden.

Eva Blondeaux, MD

Risk-Reducing Surgery Linked to Survival in Young BRCA Carriers

Genetics & Breast Cancer

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

Latest News

Risk Relapse Score for ANCA-Associated Vasculitis Treated With CYC

ERA Congress 2024

Researchers developed a method to score predictors of relapse in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis having cyclophosphamide therapy.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe